Tumor-Associated Antigens

Identification, Characterization, and Clinical Applications

Gires, Olivier / Seliger, Barbara (Editor)

1. Edition March 2009
XXI, 362 Pages, Hardcover
11 Pictures (8 Colored Figures)
16 tables
Handbook/Reference Book

ISBN: 978-3-527-32084-4

Wiley-VCH, Weinheim

Wiley Online Library Content Sample Chapter Index

Short Description

This very first comprehensive resource on the topic covers basic knowledge, identification technologies as well as examples of successful clinical application. A must-have for biologists and oncologists in science, clinics and industry.

Buy now

Price: 102,00 €

Price incl. VAT, excl. Shipping

Euro prices for Wiley-VCH and Ernst & Sohn titles are only valid for Germany. In EU countries, local VAT applies. Postage will be charged.

- Out of print -

Further versions

The first comprehensive and most recent overview of the topic, this ready reference and handbook reviews current knowledge of TAAs, their subclasses, and pinpoints their application areas in medicine. In addition, it emphasizes target identification procedures, the need for an accurate and thorough analysis of the function of TAAs, and the validation of those in clinical settings. The whole is rounded off with an overview of currently approved therapeutic antibodies.
The result is a must-have for biologists and oncologists in science, clinics and industry.

TUMOUR-ASSOCIATED ANTIGENS (TAAS): SUBCLASSES OF TAAS
T cell Antigens in Cancer (A. Paschen)
Human Tumour Antigens, Immunosurveillance, and Cancer Vaccines (O.J. Finn)
METHODS TO DETECT TAAS
Humoral Antigens in Cancer: Serological Identification Methods, Part I: SEREX (M. Pfreundschuh)
Humoral Antigens in Cancer: Serological Identification Methods, Part II: Proteomex and AMIDA (B. Seliger, O. Gires)
cDNA and Microarray-Based Technologies (F. Marincola, Ena Wang)
Detection and Identification of TAA by SELDI-TOF (F. von Eggeling, C. Melle)
TAAS AND THEIR USEFULNESS
Minor Histocompatibility Antigens and TAAs for Pediatric Cancers (U. Behrends, J. Mautner)
TAAs and their Regulation/Epigenetics (M. Maio)
Cancer-Testis Antigens (CT-antigens) (J.S. Cebon)
Animal Models for TAAs (P. McLaughlin)
Epithelial Cell Adhesion Molecule EpCAM in cancer (CD326) (P.A Baeuerle, G. Riethmüller)
Carcinoembryonic Antigen CEA (W. Zimmermann, R. Kammerer)
Her2/neu and Herceptin (B. Seliger)
Epstein-Barr Virus (EBV) Tumour-Associated Antigens (C. Mancao, W. Hammerschmidt)
Human Papilloma Virus (HPV) Tumour-Associated Antigens (A. Kaufmann)
Circulating TAAs: Biomarkers for Ovarian Cancer Diagnosis (E. Seregni, E. Bombardieri)
CLINICAL APPLICATIONS OF TAAS
Cancer Vaccines (A. Dalgleish)
Peptide Vaccination (D.P. Fairlie)
DNA Vaccination: Human Papilloma Virus (T.C. Wu)
Adoptive T cell transfer (A. Moosmann, A. Krackhardt)

Olivier Gires is a group leader at the ENT research department, Munich Medical Center, Germany and leading head of the Clinical Cooperation Group Molecular Oncology at the GSF. In 1999, he obtained his PhD in biology for his work on Epstein-Barr virus´ oncoprotein LMP1. Thereafter, Olivier Gires focused on the identification and molecular characterization of tumor-associated antigens with particular emphasis on the elucidation of the function of the therapeutic target EpCAM. Work by his group unraveled the oncogenic potential of EpCAM along with underlying molecular mechanisms. Additionally, he was decisively involved in the development of the target identification technology AMIDA.

B. Seliger, Martin-Luther-University, Halle, Germany